HE4 and CA-125 kinetics to predict outcome in patients with recurrent epithelial ovarian carcinoma: the META4 clinical trial

HE4 and CA-125 are used for epithelial ovarian cancer (EOC) screening, diagnosis, and follow-up. Our objective was to study HE4 and CA-125 kinetics in patients treated for recurrent EOC. Serum samples were prospectively collected before the first chemotherapy cycle and every 3 months until disease p...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2024-01, Vol.13, p.1308630
Main Authors: Fabbro, Michel, Lamy, Pierre-Jean, Touraine, Célia, Floquet, Anne, Ray-Coquard, Isabelle, Mollevi, Caroline
Format: Article
Language:English
Subjects:
biomarkers kinetic
CA-125
epithelial ovarian carcinoma
HE4
HE4 epithelial ovarian carcinoma
Life Sciences
Oncology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HE4 and CA-125 are used for epithelial ovarian cancer (EOC) screening, diagnosis, and follow-up. Our objective was to study HE4 and CA-125 kinetics in patients treated for recurrent EOC. Serum samples were prospectively collected before the first chemotherapy cycle and every 3 months until disease progression. Data from 89/101 patients could be analyzed. At baseline, the median CA-125 and HE4 concentrations were 210 IU/L (7–10,310) and 184 pM (31–4,836). Among the 12 patients (13%) with normal CA-125 (
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1308630